Table 3.
Logistic regression analysis concerning age, gender, renal function and medications in relation to the population with HF diagnoses and the population with no diagnosis of HF and BNP > 100 ng/L
| Variable | HF diagnoses (n = 66) | No HF diagnoses and BNP > 100 ng/L (n = 154) | p-value | OR | CI 95% for OR |
|---|---|---|---|---|---|
| Age (years) |
86.8 ± 5.6 (n = 66) |
87.0 ± 6.0 (n = 66) |
0.82 |
1.02 |
0.94-1.08 |
| Male sex n (%) |
20 (30.3) |
44 (28.6) |
0.91 |
0.96 |
0.44-2.10 |
| eGFR (ml/min/1.73 m2) |
35.9 ± 16.4 (n = 62) |
42.1 ± 15.4 (n = 152) |
0.27 |
0.99 |
0.96-1.01 |
| ACE inhibitors/ARBs |
33 (50) |
23 (14.9) |
<0.001 |
11.27 |
3.14-40.41 |
| Beta-blockers |
39 (59.1) |
70 (45.5) |
0.99 |
1.00 |
0.48-2.08 |
| Spironolactone |
10 (15.2) |
8 (5.2) |
0.04 |
3.55 |
1.08-11.68 |
| Digoxin |
16 (24.2) |
14 (9.1) |
0.31 |
1.66 |
0.62-4.43 |
| Furosemide/loop diuretics |
50 (75.8) |
50 (32.5) |
<0.001 |
5.97 |
2.39-14.92 |
| Loop diuretics with simultaneous ACE inhibitor/ARB treatment | 24 (36.4) | 35 (22.7) | 0.08 | 0.25 | 0.05-1.16 |
Nagelkerke R2 0.34.
Hosmer and Lemeshow test p-value 0.74.